Jeremy Levin

CEO and Chairman at Ovid Therapeutics Inc

Speaker

Dr. Levin has held leadership roles in major pharmaceutical and biotechnology companies, contributing significantly to the industry. He is currently Chairman and CEO of Ovid Therapeutics and Chairman of Opthea. Previously, he served as President and CEO of Teva Pharmaceutical Industries and was on Bristol-Myers Squibb’s Executive Committee, where he led the transformative “String of Pearls” strategy in immuno-oncology. He has also been Global Head of Strategic Alliances at Novartis and holds numerous board positions. Dr. Levin serves on the Board and Executive Committee of the Biotechnology Innovation Organization (BIO) as Emeritus Chairman.
He earned a BA in Zoology, an MA, and a DPhil in Chromatin Structure from Oxford University, followed by medical degrees from Cambridge University, where he won the Kermode Prize for his work on Captopril. In 2019, he published Biotechnology in the Time of COVID-19, detailing the industry's early efforts to create vaccines and treatments for the pandemic. He has received numerous awards and recognitions, including the Scrip Lifetime Achievement Award in 2023, being named by Endpoints as one of 60 living pioneers of the industry, one of the 25 most influential biotechnology leaders by Fierce Biotech, and one of the top 3 biotech CEOs by The Healthcare Technology Report. Among his other honors are the Albert Einstein Award for Leadership in Life Sciences and the B’nai B’rith Award for Distinguished Achievement.
Dr. Levin has lived in South Africa, Israel, Switzerland, the UK, and now resides in the US.